Voriconazole-induced QT prolongation among hemato-oncologic patients: clinical characteristics and risk factors

Voriconazole-induced QT prolongation among hemato-oncologic patients: clinical characteristics... Purpose The purpose of this study is to determine the rate of tients treated with voriconazole are at increased risk for QTcP, QTcP and associated risk factors in patients treated with especially in the presence of baseline QTc ≥ 450 msec and low voriconazole. serum potassium levels. Methods We conducted a retrospective chart review of all . . patients treated with voriconazole in a large tertiary center Keywords Voriconazole QT prolongation Adverse . . between 2009 and 2015, using paired comparison of QTc effects Torsadedepointes Safety intervals on and off voriconazole treatment, adjusted for co- morbidities, electrolyte abnormalities, and concurrent medications. Background Results Fifty-four patients were included, of whom 53 were diagnosed with oncologic/hemato-oncologic disease. Mean Voriconazoleisapotentantifungalagentmainlyusedinimmune- QTc during voriconazole therapy (448.0 ± 52.9 msec) was compromised hemato-oncologic patients suffering from inva- significantly longer compared to QTc off voriconazole sive aspergillosis or candida infections [1]. Among the various (421.8 ± 42.2 msec; p = 0.002). QTcP ≥30 msec and ≥60 msec adverse events that have been associated with voriconazole, was demonstrated in 43% (23 patients) and 28% (15 patients), corrected QT interval prolongation (QTcP) is the most respectively. Multivariate analysis showed that QTcP was sig- concerning given its propensity http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png European Journal of Clinical Pharmacology Springer Journals

Voriconazole-induced QT prolongation among hemato-oncologic patients: clinical characteristics and risk factors

Loading next page...
 
/lp/springer_journal/voriconazole-induced-qt-prolongation-among-hemato-oncologic-patients-F0JH7Ek0m0
Publisher
Springer Berlin Heidelberg
Copyright
Copyright © 2017 by Springer-Verlag GmbH Germany
Subject
Biomedicine; Pharmacology/Toxicology
ISSN
0031-6970
eISSN
1432-1041
D.O.I.
10.1007/s00228-017-2284-5
Publisher site
See Article on Publisher Site

Abstract

Purpose The purpose of this study is to determine the rate of tients treated with voriconazole are at increased risk for QTcP, QTcP and associated risk factors in patients treated with especially in the presence of baseline QTc ≥ 450 msec and low voriconazole. serum potassium levels. Methods We conducted a retrospective chart review of all . . patients treated with voriconazole in a large tertiary center Keywords Voriconazole QT prolongation Adverse . . between 2009 and 2015, using paired comparison of QTc effects Torsadedepointes Safety intervals on and off voriconazole treatment, adjusted for co- morbidities, electrolyte abnormalities, and concurrent medications. Background Results Fifty-four patients were included, of whom 53 were diagnosed with oncologic/hemato-oncologic disease. Mean Voriconazoleisapotentantifungalagentmainlyusedinimmune- QTc during voriconazole therapy (448.0 ± 52.9 msec) was compromised hemato-oncologic patients suffering from inva- significantly longer compared to QTc off voriconazole sive aspergillosis or candida infections [1]. Among the various (421.8 ± 42.2 msec; p = 0.002). QTcP ≥30 msec and ≥60 msec adverse events that have been associated with voriconazole, was demonstrated in 43% (23 patients) and 28% (15 patients), corrected QT interval prolongation (QTcP) is the most respectively. Multivariate analysis showed that QTcP was sig- concerning given its propensity

Journal

European Journal of Clinical PharmacologySpringer Journals

Published: Jun 17, 2017

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off